Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations
| Autor: | Maja Stojiljkovic, Biljana Stankovic, Kristel Klaassen, Bojan Ristivojevic, Branka Zukic, Sonja Pavlovic, Vladimir Gasic, Nikola Kotur |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
030213 general clinical medicine medicine.medical_specialty Clinical Biochemistry Population 030209 endocrinology & metabolism lcsh:Biochemistry 03 medical and health sciences 0302 clinical medicine Internal medicine Genotype medicine lcsh:QD415-436 1000 Genomes Project education Allele frequency azithromycin education.field_of_study Original Paper biology business.industry Biochemistry (medical) COVID-19 Lopinavir chloroquine/hydroxychloroquine 3. Good health lopinavir ritonavir covid-19 Pharmacogenomics biology.protein population pharmacogenomics Ritonavir SLCO1B1 business medicine.drug pharmacogenomics markers |
| Zdroj: | Journal of Medical Biochemistry, Vol 39, Iss 4, Pp 488-499 (2020) Journal of Medical Biochemistry (2020) 39(4):488-499 J Med Biochem |
| ISSN: | 1452-8266 1452-8258 |
| Popis: | Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk of developing adverse reactions and treatment failure in COVID-19 patients. Aim of our study was to identify pharmacogenes and pharmacogenomics markers associated with drugs recommended for COVID-19 treatment, chloroquine/hydroxychloroquine, azithromycin, lopinavir and ritonavir, in population of Serbia and other world populations.Genotype information of 143 individuals of Serbian origin was extracted from database previously obtained using TruSight One Gene Panel (Illumina). Genotype data of individuals from different world populations were extracted from the 1000 Genome Project. Fisher's exact test was used for comparison of allele frequencies.We have identified 11 potential pharmacogenomics markers in 7 pharmacogenes relevant for COVID-19 treatment. Based on high alternative allele frequencies in population and the functional effect of the variants,Considering population specific pharmacogenomics landscape, preemptive testing for pharmacogenes relevant for drugs used in COVID-19 treatment could contribute to better understanding of the inconsistency in therapy response and could be applied to improve the outcome of the COVID-19 patients.Kako ne postoje odobreni terapeutici za lečenje pacijenata sa COVID-19, mogućnost upotrebe postojećih lekova je postala važna. U nedostatku vremena za testiranje farmakogenomskih markera kod pojedinaca, populaciona farmakogenomika bi mogla biti od koristi u predviđanju povećanog rizika za pojavu neželjenih reakcija i neuspeha lečenja kod pacijenata sa COVID-19. Cilj naše studije bio je identifikovanje farmakogena i farmakogenomskih markera povezanih sa lekovima koji se preporučuju za lečenje COVID-19, hlorokin/hidroksihlorokin, azitromicin, lopinavir i ritonavir, u populaciji Srbije i drugim svetskim populacijama.Podaci o genotipu 143 osobe srpskog porekla dobijeni su iz baze podataka prethodno formirane analizama genoma korišćenjem TruSight One Gene Panel (Illumina). Podaci o genotipu pojedinaca iz različitih svetskih populacija dobijeni su iz Projekta 1000 genoma. Fišerov egzaktni test korišćen je za poređenje učestalosti alela.Identifikovali smo 11 potencijalnih farmakogenomskih markera u 7 farmakogena značajnih za lečenje COVID-19. Na osnovu visoke alterativne učestalosti alela u populaciji Srbije i funkcionalnog efekta varijanti,Uzimajući u obzir farmakogenomski profil specifičan za populaciju, preventivno testiranje farmakogena značajnih za lekove koji se koriste u lečenju COVID-19 moglo bi doprineti boljem razumevanju interindividualnih razlika u odgovorima na terapiju i poboljšanju ishoda lečenja pacijenata sa COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|